KBC Group NV Increases Stake in Krystal Biotech, Inc. (NASDAQ:KRYS)

KBC Group NV boosted its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 25.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 642 shares of the company’s stock after acquiring an additional 132 shares during the quarter. KBC Group NV’s holdings in Krystal Biotech were worth $117,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of the company. Price T Rowe Associates Inc. MD raised its holdings in Krystal Biotech by 54.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 658,618 shares of the company’s stock valued at $117,189,000 after acquiring an additional 231,255 shares in the last quarter. Principal Financial Group Inc. lifted its holdings in Krystal Biotech by 1,972.0% in the second quarter. Principal Financial Group Inc. now owns 123,469 shares of the company’s stock worth $22,674,000 after purchasing an additional 117,510 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Krystal Biotech by 115.7% in the second quarter. Bank of New York Mellon Corp now owns 193,767 shares of the company’s stock valued at $35,583,000 after acquiring an additional 103,928 shares in the last quarter. Capital World Investors bought a new position in Krystal Biotech during the 1st quarter valued at $17,285,000. Finally, Public Sector Pension Investment Board acquired a new position in Krystal Biotech during the second quarter worth about $10,037,000. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Insider Buying and Selling at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the transaction, the insider now directly owns 1,500,882 shares in the company, valued at $296,814,424.32. The trade was a 1.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 14.10% of the company’s stock.

Krystal Biotech Price Performance

Shares of Krystal Biotech stock opened at $182.29 on Friday. The firm has a market cap of $5.24 billion, a price-to-earnings ratio of 102.99 and a beta of 0.82. The stock’s 50-day moving average is $180.03 and its 200-day moving average is $181.99. Krystal Biotech, Inc. has a one year low of $99.00 and a one year high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.84 by $0.07. The company had revenue of $83.84 million for the quarter, compared to the consensus estimate of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The firm’s revenue was up 879.9% compared to the same quarter last year. During the same period last year, the company earned ($0.67) earnings per share. On average, equities analysts expect that Krystal Biotech, Inc. will post 2.97 EPS for the current year.

Analysts Set New Price Targets

Several research analysts recently weighed in on KRYS shares. William Blair raised Krystal Biotech to a “strong-buy” rating in a research report on Friday, August 30th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Krystal Biotech in a research note on Thursday, August 29th. Citigroup upped their price target on Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. HC Wainwright reaffirmed a “buy” rating and set a $221.00 price objective on shares of Krystal Biotech in a research report on Tuesday, November 5th. Finally, Chardan Capital lifted their price target on shares of Krystal Biotech from $153.00 to $208.00 and gave the stock a “buy” rating in a research note on Monday, August 5th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Krystal Biotech has an average rating of “Buy” and a consensus target price of $202.29.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).